BackEntrada Therapeutics Overview

Entrada Therapeutics Accounts Payable

Track Entrada Therapeutics's accounts payable ($2.9M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Accounts Payable
$2.93M
↑ 33.91% YoYΔ $742000.00 vs prior year quarter

Peer average

Loading

Entrada Therapeutics Accounts Payable History

Loading

Entrada Therapeutics vs. peers: Accounts Payable Comparison

Loading

Entrada Therapeutics Accounts Payable Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Entrada Therapeutics (TRDA) FAQ

As of the most recent data (March 2026), TRDA shows a accounts payable of $2.9M. That compares with $2.2M in the prior-year period — up 33.9% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, TRDA's accounts payable is now $2.9M (was $2.2M) — a 33.9% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Entrada Therapeutics is outperforming or lagging.

Tracking TRDA's accounts payable over time shows whether Entrada Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $2.9M That compares with $2.2M in the prior-year period — up 33.9% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this accounts payable page, Stockcircle has Entrada Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect accounts payable (currently $2.9M) with ownership activity and broader fundamentals.